Top in hem/onc: Wealth management, cell therapy for diabetes
Click Here to Manage Email Alerts
Experts said President Joe Biden plans to increase taxes on high-income taxpayers, but physicians can still benefit from two assets: real estate and permanent life insurance.
This guide to wealth planning was the top story in hematology/oncology last week.
Another top story was about Lantidra (donislecel, CellTrans), an allogeneic pancreatic islet cellular therapy. An FDA panel recently concluded that the benefits of this treatment outweigh the risks for certain patients with type 1 diabetes.
Read these and more top stories in hematology/oncology below:
Real estate, permanent life insurance provide tax benefits
In any year, most physicians would like to reduce their taxes. This goal may prove even more important in 2021, and beyond, as it is expected that Democratic control of Congress and the White House will result in new tax legislation. Read more.
Benefits of cell therapy for type 1 diabetes outweigh risks, FDA panel concludes
An FDA advisory committee concluded that the investigational cell therapy donislecel demonstrated a favorable risk-benefit profile for certain patients with difficult-to-control type 1 diabetes. Read more.
Personalized vaccine shows potential benefit across cancer types
A personalized genomic vaccine administered after standard-of-care adjuvant therapy appeared to be safe and induced immunogenicity among patients with different cancers at a high risk for recurrence, according to results of a phase 1 trial. Read more.
Women with ovarian cancer at higher risk for mental health disorders
Women with ovarian cancer appeared to be at greater risk for anxiety, depression and adjustment disorder within the first 2 years of diagnosis than women in the general population, study results showed. Read more.
Tumor-infiltrating lymphocytes show ‘dramatic’ results in metastatic melanoma
More than 80% of patients with heavily pretreated metastatic melanoma experienced tumor shrinkage after receiving the adoptive cell therapy LN-144 (lifileucel, Iovance Biotherapeutics), according to results of a phase 2 study. Read more.